Results 21 to 30 of about 17,763 (261)
Candida auris, what do paediatricians need to know? [PDF]
, 2018 AW is supported by the Wellcome Trust Strategic Award (grant 097377) and the MRC Centre for Medical Mycology (grant MR/N006364/1) at the University of Aberdeen.Peer reviewedPublisher ...
Warris, Adilia
core +1 more source
Caspofungin Treatment of Aspergillus fumigatus Results in ChsG-Dependent Upregulation of Chitin Synthesis and the Formation of Chitin-Rich Microcolonies [PDF]
, 2015 Date of Acceptance: 23/07/2015 We thank Gillian Milne for help with electron microscopy, Sophie M. Schäfer for pilot experiments, and Emilia Mellado for strains. All authors acknowledge financial support of Gilead Sciences through Ph.D.
Gow, Neil A R +3 more
core +1 more source
Micafungin: A New Echinocandin [PDF]
Clinical Infectious Diseases, 2006 Micafungin, a potent inhibitor of 1,3-beta-D-glucan synthase, has become the second available agent in the echinocandins class that is approved for use in clinical practice. This agent shares with caspofungin an identical spectrum of in vitro activity against Candida albicans, non-albicans species of Candida, and Aspergillus species, as well as several
P H, Chandrasekar, J D, Sobel
openaire +2 more sources
Candida auris Bloodstream Infections in Russia
Antibiotics, 2020 Candida auris—a fungus (yeast) that can cause hospital outbreaks was first recognized in 2009. The authors report data on 38 cases of C. auris bloodstream infections in multidisciplinary hospitals situated in two distantly located regions of Russia ...
Natalia E. Barantsevich +4 more
doaj +1 more source
Molecular Mechanisms Associated with Antifungal Resistance in Pathogenic Candida Species
Cells, 2023 Candidiasis is a highly pervasive infection posing major health risks, especially for immunocompromised populations. Pathogenic Candida species have evolved intrinsic and acquired resistance to a variety of antifungal medications.
Karolina M. Czajka +8 more
doaj +1 more source
First hospital outbreak of the globally emerging Candida auris in a European hospital [PDF]
, 2016 Background: Candida auris is a globally emerging multidrug resistant fungal pathogen causing nosocomial transmission. We report an ongoing outbreak of C. auris in a London cardio-thoracic center between April 2015 and July 2016.
Abdolrasouli, A +11 more
core +2 more sources
Journal of Fungi, 2023 Candida parapsilosis is the second most common Candida species isolated in Asia, Southern Europe, and Latin America and is often involved in invasive infections that seriously impact human health. This pathogen is part of the psilosis complex, which also
Joana Branco +2 more
doaj +1 more source
Bloodstream yeast infections: a 15-month survey [PDF]
, 2009 A 15-month survey of 412 bloodstream yeast isolates from 54 Belgian hospitals was undertaken. Candida albicans was the most common species (47.3%) followed by C. glabrata (25.7%), C. parapsilosis (8.0%), C. tropicalis (6.8%) and Saccharomyces cerevisiae (
Detandt, M +3 more
core +1 more source
Cdc14 phosphatase contributes to cell wall integrity and pathogenesis in Candida albicans
Frontiers in Microbiology, 2023 The Cdc14 phosphatase family is highly conserved in fungi. In Saccharomyces cerevisiae, Cdc14 is essential for down-regulation of cyclin-dependent kinase activity at mitotic exit.
Kedric L. Milholland +15 more
doaj +1 more source
The importance of subclasses of chitin synthase enzymes with myosin-like domains for the fitness of fungi [PDF]
, 2016 Acknowledgements TG and CF are funded by FEDER funds through the Operational Programme Competitiveness Factors – COMPETE and national funds by FCT – Foundation for Science and Technology under the strategic project UID/NEU/04539/2013. C.F. is a recipient
Fernandes, Chantal +2 more
core +1 more source